Inmune Bio, Inc.
Clinical trials sponsored by Inmune Bio, Inc., explained in plain language.
Clinical-stage biopharmaceutical company developing immunotherapies for cancer and inflammation.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug targets brain inflammation to slow Alzheimer's
Disease control CompletedThis study tested an experimental drug called XPro1595 in 208 people with early Alzheimer's disease who also had signs of brain inflammation. The goal was to see if the drug could improve memory, thinking, and daily function compared to a placebo over 24 weeks. Researchers also c…
Phase 2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental cell therapy aims to boost immune system against Hard-to-Treat prostate cancer
Disease control CompletedThis early-phase trial tested an experimental cell therapy called INKmune in 12 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find the safest and most effective dose by measuring immune cell activity, PSA levels, and tumor changes. …
Phase 1/2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC